Gene Mack

In a report published Friday, Brean Capital analyst Gene Mack reiterated a Buy rating on Celgene Corporation (NASDAQ: CELG), and raised the price target from $153.00 to $191.00. In the report, Brean Capital noted, “CELG reported 3Q13 of $1.56 per share, beating our $1.50 estimate and inline with...

Celgene (NASDAQ: CELG) stock still has growth potential left in it. The stock has notched up 45 percent over the last 12 months. The company is growing its profits. Barron’s reported that the stock is currently trading at 22 times earnings, but still it has the potential to grow 30% or more. Gene...